CERo Therapeutics Holdings, Inc. (CERO)
OTCMKTS
· Delayed Price · Currency is USD
0.1067
-0.0063 (-5.56%)
At close: Dec 5, 2025
CERo Therapeutics Holdings Company Description
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer.
Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors.
The company was incorporated in 2021 and is based in South San Francisco, California.
CERo Therapeutics Holdings, Inc.
| Country | United States |
| Founded | 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Christopher Ehrlich |
Contact Details
Address: 201 Haskins Way South San Francisco, Delaware 94080 United States | |
| Phone | (650) 407-2376 |
| Website | cero.bio |
Stock Details
| Ticker Symbol | CERO |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US71902K3032 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Christopher B. Ehrlich M.B.A. | Chief Executive Officer and Chair |
| Andrew Albert Kucharchuk M.B.A. | Chief Financial Officer |
| Dr. Kristen Pierce Ph.D. | Chief Development Officer |
| Dr. Lawrence Corey M.D. | Co-founder and Head of Scientific Advisory Board |